Filtered By:
Specialty: Drugs & Pharmacology
Cancer: Prostate Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 653 results found since Jan 2013.
Androgen receptor and hyaluronan-mediated motility receptor as new molecular targets of baicalein: new molecular mechanisms for its anticancer properties
Arch Pharm Res. 2023 Sep 10. doi: 10.1007/s12272-023-01461-2. Online ahead of print.ABSTRACTNatural compounds known as phytochemicals have served as valuable resources for the development of new anti-cancer drugs and treatment of malignancies. Among these phytochemicals, baicalein is an emerging anti-tumor flavonoid obtained from Scutellaria baicaleinsis (Lamiaceae), but its underlying mechanisms of action and molecular targets have not yet been completely elucidated. Here, we identified new mechanisms for the anti-tumor activities of baicalein, providing evidence that hyaluronan-mediated motility receptor (HMMR) and andro...
Source: Archives of Pharmacal Research - September 10, 2023 Category: Drugs & Pharmacology Authors: Mingyue Jiang Suman Poudel Kyung Song Source Type: research
Antitumor activity of alkylphospholipid edelfosine in prostate cancer models and endoplasmic reticulum targeting
Biomed Pharmacother. 2023 Sep 6;167:115436. doi: 10.1016/j.biopha.2023.115436. Online ahead of print.ABSTRACTProstate cancer is the second most frequent cancer and the fifth leading cause of cancer death among men worldwide. While the five-year survival in local and regional prostate cancer is higher than 99%, it falls to about 28% in advanced metastatic prostate cancer. The ether lipid edelfosine is considered the prototype of a family of promising antitumor drugs collectively named as alkylphospholipid analogs. Here, we found that edelfosine was the most potent alkylphospholipid analog in inducing apoptosis in three diff...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 8, 2023 Category: Drugs & Pharmacology Authors: El-Habib Dakir Consuelo Gajate Faustino Mollinedo Source Type: research
Targeted inhibition of mTOR by BML-275 induces mitochondrial-mediated apoptosis and autophagy in prostate cancer
In this study, BML-275 was demonstrated to exert potent antitumor effects in PCa by antagonizing mTOR activity. In cultured PCa cells, BML-275 treatment reduced the expression levels of c-Myc and survivin, promoted the activation of p53, and thereby induced p21/cyclin D1/CDK4/6-dependent cell cycle G1/S arrest. As a result, BML-275 inhibited cellular proliferation and induced mitochondrial-mediated apoptosis. In addition, BML-275 treatment triggered autophagy. Interestingly, EACC-mediated suppression of autophagy did not affect BML-275-induced proliferation and apoptosis. Nude mouse tumorigenic experiments also confirmed t...
Source: European Journal of Pharmacology - September 1, 2023 Category: Drugs & Pharmacology Authors: Wangjian Li Dongzhang Li Quan Ma Yongliang Chen Zujian Hu Yongheng Bai Liping Xie Source Type: research
Effect of aspirin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from randomized controlled trials and real-world studies
ConclusionsThis meta-analysis revealed an independent correlation between the use of aspirin and reductions in both the incidence and mortality rates of PCa. However, randomized controlled trials did not find any association between aspirin use and PCa. Furthermore, the impact of aspirin on PCa occurrence was found to be dependent on both dosage and duration.
Source: European Journal of Clinical Pharmacology - August 30, 2023 Category: Drugs & Pharmacology Source Type: research
Suppression of hypothalamic-pituitary-gonadal function by linzagolix in benign prostatic hyperplasia and polycystic ovary syndrome animal models
Clin Exp Pharmacol Physiol. 2023 Aug 25. doi: 10.1111/1440-1681.13817. Online ahead of print.ABSTRACTThe hypothalamic-pituitary-gonadal (HPG) axis is an important regulatory mechanism involved primarily in the development and regulation of the reproductive systems. The suppression of the HPG axis by gonadotropin-releasing hormone (GnRH) analogues is expected to be effective for the treatment of sex hormone-dependent diseases, such as endometriosis, uterine fibroid, prostate cancer, benign prostatic hyperplasia (BPH) and polycystic ovary syndrome (PCOS). Despite the established involvement of GnRH signalling in these disord...
Source: Clinical and Experimental Pharmacology and Physiology - August 25, 2023 Category: Drugs & Pharmacology Authors: Motohiro Tezuka Saori Yonekubo-Awaka Yasuaki Tamai Kumi Tsuchioka Kaoru Kobayashi Yu Kuramochi Satoshi Tatemichi Tatsuya Nagasawa Sumiyoshi Kiguchi Source Type: research
Authors Reply to Comment on Rotshild et al's "The Risk for Prostate Cancer With Calcium Channel Blockers"
Ann Pharmacother. 2023 Aug 23:10600280231185784. doi: 10.1177/10600280231185784. Online ahead of print.NO ABSTRACTPMID:37614020 | DOI:10.1177/10600280231185784
Source: The Annals of Pharmacotherapy - August 24, 2023 Category: Drugs & Pharmacology Authors: Victoria Rotshild Ilan Matok Source Type: research
